FREELINE
LIVE

Serial Number

79255127

Owner

Freeline Therapeutics Limited

Attorney

Samantha M. Quimby

Filing Date

Nov 23, 2018

Add to watchlist:

No watchlists yet
View on USPTO

FREELINE Trademark

Serial Number: 79255127 • Registration: 5999142

FREELINE is a trademark filed by Freeline Therapeutics Limited on November 23, 2018. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

Freeline Therapeutics Limited (4 trademarks)

Sycamore House,

Entity Type: 99

Trademark Details

Filing Date

November 23, 2018

Registration Date

March 3, 2020

Published for Opposition

December 17, 2019

Goods & Services

Pharmaceutical, medical and veterinary preparations for prevention, amelioration or treatment of disorders, namely blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders, cancers or infectious diseases; pharmaceutical, medical and clinical preparations for therapeutic or prophylactic purposes in connection with blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders, cancers or infectious diseases; pharmaceutical, medical and clinical preparations for use in treatment, amelioration or prophylaxis of genetic or inherited or non-infectious diseases or disorders, namely blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders or cancers; pharmaceutical, medical and clinical preparations for treatment, amelioration or prophylaxis of chronic or systemic disease, namely blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders or cancers; pharmaceutical, medical and clinical preparations for use in gene therapy for prevention, amelioration or treatment of disorders, namely of blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders, cancers or infectious diseases; pharmaceutical, medical and clinical preparations for liver-targeted viral gene therapy; genetic medicines for prevention, amelioration or treatment of disorders, namely blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders, cancers or infectious disease; preparations for therapeutic delivery of nucleic acids; viral or nucleic acid vectors for therapeutic or prophylactic purposes or preparations containing such vectors; adeno-associated viral gene therapy preparations for prevention, amelioration or treatment of disorders, namely blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders, cancers or infectious diseases

Filing History

COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Mar 3, 2025 REM3
CHANGE OF NAME/ADDRESS REC'D FROM IB
Feb 6, 2023 ADCH
NEW REPRESENTATIVE AT IB RECEIVED
Aug 15, 2022 NREP
FINAL DECISION TRANSACTION PROCESSED BY IB
Jul 24, 2020 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Jul 8, 2020 FICS
FINAL DISPOSITION PROCESSED
Jul 8, 2020 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jun 3, 2020 FICR
REGISTERED-PRINCIPAL REGISTER
Mar 3, 2020 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 17, 2019 NPUB
PUBLISHED FOR OPPOSITION
Dec 17, 2019 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 27, 2019 NONP
ASSIGNED TO LIE
Nov 12, 2019 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 7, 2019 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 6, 2019 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 6, 2019 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 6, 2019 TROA
REFUSAL PROCESSED BY IB
Jun 14, 2019 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
May 8, 2019 RFCS
REFUSAL PROCESSED BY MPU
May 7, 2019 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Apr 17, 2019 RFCR
NON-FINAL ACTION WRITTEN
Apr 16, 2019 CNRT
APPLICATION FILING RECEIPT MAILED
Apr 2, 2019 MAFR
ASSIGNED TO EXAMINER
Mar 27, 2019 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 27, 2019 NWOS
LIMITATION FROM ORIGINAL APPLICATION ENTERED
Mar 25, 2019 LIMI
SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB
Mar 21, 2019 SDRC